(Q53502910)

14 May 2018

title

GLP-1 receptor agonists and heart failure in diabetes. (English)

1 reference

14 May 2018

0 references

André J Scheen

1

1 reference

14 May 2018

publication date

1 April 2017

1 reference

14 May 2018

published in

Diabetes and Metabolism

1 reference

14 May 2018

volume

43 Suppl 1

1 reference

14 May 2018

page(s)

2S13-2S19

1 reference

14 May 2018

Type 2 Diabetes and Heart Failure: Challenges and Solutions.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Type 1 diabetes, hyperglycaemia, and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial".

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular actions of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular Effects of Incretin-Based Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Glucagon-like peptide 1 and cardiac cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930068-X

7 January 2021

10.1016/S1262-3636(17)30068-X

Identifiers

DOI

1 reference

14 May 2018

PubMed ID

28431666

1 reference

14 May 2018